Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:alditol derivative
go back to main search page
Accession:CHEBI:63423 term browser browse the term
Definition:A carbohydrate derivative that is formally obtained from an alditol.
Synonyms:related_synonym: alditol derivatives
 cyclic_relationship: has_functional_parent CHEBI:17522


show annotations for term's descendants           Sort by:
1,2-dioctanoyl-sn-glycero-3-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO dioctanoylphosphatidic acid results in increased expression of PTGS2 protein CTD PMID:11854442 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
1-octadec-9-enoylglycero-3-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle increases expression
multiple interactions 		ISO lysophosphatidic acid results in increased expression of ACTA2 mRNA
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA] 		CTD PMID:24706986 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation 		ISO
EXP 		2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] 		CTD PMID:14769825 PMID:17550345 PMID:20103642 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions ISO ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]] CTD PMID:10698703 NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated multiple interactions ISO [Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein CTD PMID:19646460 NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167 		JBrowse link
G Bcar1 BCAR1 scaffold protein, Cas family member increases phosphorylation ISO lysophosphatidic acid results in increased phosphorylation of BCAR1 protein CTD PMID:11792571 NCBI chr19:56,588,500...56,623,190
Ensembl chr19:56,588,500...56,623,190 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO lysophosphatidic acid analog results in increased expression of BCL2 protein; lysophosphatidic acid results in increased expression of BCL2 protein CTD PMID:23251428 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G C5 complement C5 increases expression ISO lysophosphatidic acid results in increased expression of HC protein CTD PMID:25822713 NCBI chr 3:38,668,174...38,759,468
Ensembl chr 3:38,668,174...38,759,468 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] CTD PMID:23251428 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Ccl12 C-C motif chemokine ligand 12 increases expression
multiple interactions 		ISO lysophosphatidic acid results in increased expression of CCL12 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein] 		CTD PMID:25822713 NCBI chr10:67,567,876...67,569,426
Ensembl chr10:67,567,876...67,569,426 		JBrowse link
G Ccl28 C-C motif chemokine ligand 28 multiple interactions
increases expression 		ISO 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL28 protein] CTD PMID:25822713 NCBI chr 2:53,334,071...53,358,709
Ensembl chr 2:53,334,071...53,358,709 		JBrowse link
G Ccn1 cellular communication network factor 1 multiple interactions
increases expression 		ISO 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCN1 protein] CTD PMID:25822713 NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883 		JBrowse link
G Ccn2 cellular communication network factor 2 increases expression
multiple interactions 		EXP
ISO 		lysophosphatidic acid results in increased expression of CCN2 protein
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA]
Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] 		CTD PMID:15200425 PMID:24706986 NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976 		JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression
multiple interactions 		ISO lysophosphatidic acid results in increased expression of COL1A2 mRNA
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA] 		CTD PMID:24706986 NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995 		JBrowse link
G Csf1 colony stimulating factor 1 increases expression ISO lysophosphatidic acid results in increased expression of CSF1 protein CTD PMID:25822713 NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 increases expression
multiple interactions 		ISO lysophosphatidic acid results in increased expression of CXCL12 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein] 		CTD PMID:25822713 NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627 		JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 increases expression
multiple interactions 		ISO lysophosphatidic acid results in increased expression of CXCL16 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein] 		CTD PMID:25822713 NCBI chr10:55,665,355...55,669,950
Ensembl chr10:55,664,742...55,670,226 		JBrowse link
G Cxcr1 C-X-C motif chemokine receptor 1 multiple interactions
decreases expression 		ISO lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein]
lysophosphatidic acid results in decreased expression of CXCR1 mRNA 		CTD PMID:16224106 NCBI chr 9:83,216,040...83,220,225
Ensembl chr 9:83,215,292...83,226,872 		JBrowse link
G Dgka diacylglycerol kinase, alpha multiple interactions ISO DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] CTD PMID:10913605 NCBI chr 7:1,733,247...1,761,181
Ensembl chr 7:1,733,248...1,759,569 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
increases phosphorylation 		ISO GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] CTD PMID:23127547 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
increases phosphorylation 		EXP 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] CTD PMID:14769825 NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874 		JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 multiple interactions
decreases expression 		ISO
EXP 		1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]
lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] 		CTD PMID:18594965 PMID:19014389 PMID:24599971 PMID:24747415 PMID:25398768 More... NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957 		JBrowse link
G Epo erythropoietin multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] CTD PMID:21915944 NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725 		JBrowse link
G Flt4 Fms related receptor tyrosine kinase 4 multiple interactions ISO FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein] CTD PMID:18642114 NCBI chr10:34,414,834...34,455,878
Ensembl chr10:34,414,733...34,456,645 		JBrowse link
G Gata1 GATA binding protein 1 multiple interactions ISO [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] CTD PMID:21915944 NCBI chr  X:17,193,291...17,209,462
Ensembl chr  X:17,201,633...17,209,459 		JBrowse link
G Gna13 G protein subunit alpha 13 multiple interactions ISO GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] CTD PMID:23127547 NCBI chr10:94,837,271...94,870,290
Ensembl chr10:94,836,444...94,874,968 		JBrowse link
G Gypa glycophorin A multiple interactions ISO lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA] CTD PMID:21915944 NCBI chr19:44,354,669...44,370,304
Ensembl chr19:44,354,706...44,370,291 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions
increases expression 		ISO L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein 		CTD PMID:17919812 PMID:22537771 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 multiple interactions
increases phosphorylation 		EXP MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein] CTD PMID:20864298 NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] CTD PMID:25896349 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il6 interleukin 6 increases secretion ISO lysophosphatidic acid results in increased secretion of IL6 protein CTD PMID:21821728 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Il6st interleukin 6 cytokine family signal transducer multiple interactions
increases expression 		ISO 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of IL6ST protein] CTD PMID:25822713 NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182 		JBrowse link
G Kitlg KIT ligand multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] CTD PMID:21915944 NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793 		JBrowse link
G Kng1 kininogen 1 multiple interactions EXP KNG1 protein inhibits the reaction [[Wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] CTD PMID:10537051 NCBI chr11:91,317,354...91,340,148
Ensembl chr11:91,317,355...91,340,148 		JBrowse link
G Lama3 laminin subunit alpha 3 increases expression ISO lysophosphatidic acid results in increased expression of LAMA3 mRNA CTD PMID:15541073 NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,797,939...4,026,449 		JBrowse link
G Lamb3 laminin subunit beta 3 increases expression ISO lysophosphatidic acid results in increased expression of LAMB3 mRNA CTD PMID:15541073 NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081 		JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression ISO lysophosphatidic acid results in increased expression of LAMC2 mRNA CTD PMID:15541073 NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102 		JBrowse link
G Lpar1 lysophosphatidic acid receptor 1 increases response to substance
multiple interactions 		ISO LPAR1 protein results in increased susceptibility to lysophosphatidic acid
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] 		CTD PMID:16224106 PMID:16809448 PMID:25398768 NCBI chr 5:78,024,139...78,147,071
Ensembl chr 5:78,024,139...78,142,188 		JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 multiple interactions ISO Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein CTD PMID:30102254 NCBI chr 2:237,785,371...237,854,199
Ensembl chr 2:237,787,766...237,854,197 		JBrowse link
G Lpar5 lysophosphatidic acid receptor 5 multiple interactions ISO Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein CTD PMID:30102254 NCBI chr 4:159,556,735...159,570,216
Ensembl chr 4:159,554,805...159,571,894 		JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 multiple interactions ISO lysophosphatidic acid binds to and results in increased activity of LPAR6 protein CTD PMID:18297070 NCBI chr15:54,826,110...54,827,919
Ensembl chr15:54,823,717...54,978,783 		JBrowse link
G Lyve1 lymphatic vessel endothelial hyaluronan receptor 1 multiple interactions
increases expression 		ISO 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of LYVE1 protein]
lysophosphatidic acid results in increased expression of LYVE1 mRNA; lysophosphatidic acid results in increased expression of LYVE1 protein 		CTD PMID:18642114 NCBI chr 1:174,393,387...174,410,977 JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation 		ISO
EXP 		Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] 		CTD PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation 		ISO
EXP 		Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] 		CTD PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mbp myelin basic protein multiple interactions EXP lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] CTD PMID:18594965 NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression 		ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]] CTD PMID:23127547 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation EXP lysophosphatidic acid results in increased phosphorylation of MTOR protein CTD PMID:14769825 NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435 		JBrowse link
G Myl9 myosin light chain 9 increases phosphorylation
multiple interactions 		ISO lysophosphatidic acid results in increased phosphorylation of MYL9 protein
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein] 		CTD PMID:24587105 NCBI chr 3:165,742,020...165,748,409
Ensembl chr 3:165,742,046...165,748,410 		JBrowse link
G Mylk myosin light chain kinase affects response to substance ISO MYLK protein affects the susceptibility to lysophosphatidic acid CTD PMID:10640419 NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein
[[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2 		CTD PMID:25398768 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nppa natriuretic peptide A multiple interactions
increases expression 		EXP Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein] CTD PMID:15081308 PMID:25449040 NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493 		JBrowse link
G Pak1 p21 (RAC1) activated kinase 1 increases activity
multiple interactions 		EXP lysophosphatidic acid results in increased activity of PAK1 protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; diphenyleneiodonium inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Genistein inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein] 		CTD PMID:11855845 NCBI chr 1:161,522,399...161,637,623
Ensembl chr 1:161,491,847...161,637,612 		JBrowse link
G Pdpn podoplanin increases expression
multiple interactions 		ISO lysophosphatidic acid results in increased expression of PDPN mRNA; lysophosphatidic acid results in increased expression of PDPN protein
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PDPN protein] 		CTD PMID:18642114 NCBI chr 5:160,884,995...160,919,112
Ensembl chr 5:160,884,993...160,925,637 		JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 increases expression
multiple interactions 		ISO lysophosphatidic acid results in increased expression of PECAM1 protein
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein] 		CTD PMID:18642114 NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839 		JBrowse link
G Pip5k1a phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha multiple interactions
increases activity 		ISO 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] CTD PMID:10913605 NCBI chr 2:185,317,319...185,361,859
Ensembl chr 2:185,317,319...185,360,476 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions
increases expression 		ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] CTD PMID:23127547 NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030 		JBrowse link
G Pld1 phospholipase D1 multiple interactions
increases activity 		EXP 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein] CTD PMID:11243883 PMID:14769825 NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:112,777,951...112,976,245 		JBrowse link
G Ppp1r12a protein phosphatase 1, regulatory subunit 12A increases phosphorylation
multiple interactions 		EXP lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein
Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein] 		CTD PMID:25449040 NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:45,369,315...45,480,157 		JBrowse link
G Prox1 prospero homeobox 1 increases expression
multiple interactions 		ISO lysophosphatidic acid results in increased expression of PROX1 mRNA; lysophosphatidic acid results in increased expression of PROX1 protein
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PROX1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein] 		CTD PMID:18642114 NCBI chr13:104,196,615...104,251,007
Ensembl chr13:104,200,378...104,250,975 		JBrowse link
G Ptk2 protein tyrosine kinase 2 increases phosphorylation
multiple interactions 		ISO
EXP 		lysophosphatidic acid results in increased phosphorylation of PTK2 protein
[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]
[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] 		CTD PMID:10537051 PMID:11792571 NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091 		JBrowse link
G Ptk2b protein tyrosine kinase 2 beta increases phosphorylation ISO lysophosphatidic acid results in increased phosphorylation of PTK2B protein CTD PMID:11792571 NCBI chr15:44,536,275...44,656,754
Ensembl chr15:44,531,249...44,656,806 		JBrowse link
G Rhoa ras homolog family member A increases activity
multiple interactions 		EXP
ISO 		lysophosphatidic acid results in increased activity of RHOA protein
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein] 		CTD PMID:15081308 PMID:24587105 NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302 		JBrowse link
G Rhoc ras homolog family member C multiple interactions
increases activity 		ISO Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein] CTD PMID:24587105 NCBI chr 2:194,975,586...194,981,637
Ensembl chr 2:194,975,242...194,983,745 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 increases phosphorylation
multiple interactions 		ISO
EXP 		lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein
resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] 		CTD PMID:14769825 PMID:17919812 NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238 		JBrowse link
G Tfrc transferrin receptor multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] CTD PMID:21915944 NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions
increases expression 		ISO 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of TIMP1 protein] CTD PMID:25822713 NCBI chr  X:3,766,509...3,772,578
Ensembl chr  X:3,766,510...3,771,135 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] CTD PMID:25896349 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression
multiple interactions 		ISO [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein
resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein] 		CTD PMID:17919812 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vegfc vascular endothelial growth factor C increases expression
increases secretion 		ISO lysophosphatidic acid results in increased expression of VEGFC mRNA
lysophosphatidic acid results in increased secretion of VEGFC protein 		CTD PMID:18642114 NCBI chr16:44,445,293...44,560,887
Ensembl chr16:44,445,293...44,560,887 		JBrowse link
glycerol 1-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G App amyloid beta precursor protein multiple interactions
decreases abundance 		ISO PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of alpha-glycerophosphoric acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid] 		CTD PMID:39172838 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Gk glycerol kinase multiple interactions EXP 1-butyrylglycerol promotes the reaction [[GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid]; [GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid; monoacetin promotes the reaction [[GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid] CTD PMID:9606984 NCBI chr  X:54,106,708...54,189,940
Ensembl chr  X:54,112,214...54,196,701 		JBrowse link
G Gpd2 glycerol-3-phosphate dehydrogenase 2 multiple interactions ISO GPD2 protein inhibits the reaction [Dihydroxyacetone results in increased abundance of alpha-glycerophosphoric acid]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of alpha-glycerophosphoric acid]; GPD2 protein inhibits the reaction [Glycerol results in increased abundance of alpha-glycerophosphoric acid] CTD PMID:31974165 NCBI chr 3:62,209,432...62,346,590
Ensembl chr 3:62,210,814...62,346,593 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of alpha-glycerophosphoric acid] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 multiple interactions ISO IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid] CTD PMID:39172838 NCBI chr16:74,133,259...74,145,328
Ensembl chr16:74,133,259...74,145,328 		JBrowse link
G Mapt microtubule-associated protein tau decreases abundance
multiple interactions 		ISO MAPT protein mutant form results in decreased abundance of alpha-glycerophosphoric acid
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of alpha-glycerophosphoric acid] 		CTD PMID:39172838 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108 		JBrowse link
G Psen1 presenilin 1 multiple interactions ISO [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid] CTD PMID:39172838 NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189 		JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions ISO [SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of RUNX2 mRNA CTD PMID:36682590 NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027 		JBrowse link
G Sp7 Sp7 transcription factor multiple interactions ISO [SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SP7 mRNA CTD PMID:36682590 NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:135,363,199...135,373,559 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA CTD PMID:36682590 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
glycerol 2-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA] CTD PMID:25932594 NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of AKT1 protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of AKT1 protein] CTD PMID:23111315 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated increases hydrolysis
multiple interactions
increases expression
increases degradation
increases activity 		ISO ALPL protein results in increased hydrolysis of beta-glycerophosphoric acid
[ALPL protein results in increased degradation of beta-glycerophosphoric acid] which results in increased abundance of Phosphates; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of ALPL mRNA; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ALPL mRNA; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ALPL mRNA]; Diphosphates inhibits the reaction [[ALPL protein results in increased degradation of beta-glycerophosphoric acid] which results in increased abundance of Phosphates]; Diphosphates inhibits the reaction [ALPL protein results in increased degradation of beta-glycerophosphoric acid]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ALPL mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA]; Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of ALPL mRNA]
beta-glycerophosphoric acid results in increased expression of ALPL mRNA
beta-glycerophosphoric acid results in increased activity of ALPL protein
[ALPL protein results in increased hydrolysis of beta-glycerophosphoric acid] which results in increased abundance of Phosphates; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein]]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased activity of ALPL protein]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of ALPL mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein] 		CTD PMID:17383965 PMID:18500657 PMID:26424790 PMID:26492236 PMID:28921615 More... NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167 		JBrowse link
G Atad2 ATPase family, AAA domain containing 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of ATAD2 mRNA CTD PMID:26424790 NCBI chr 7:91,523,626...91,566,238
Ensembl chr 7:91,523,626...91,566,238 		JBrowse link
G Atad2b ATPase family, AAA domain containing 2B multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ATAD2B mRNA CTD PMID:26424790 NCBI chr 6:33,646,075...33,789,532
Ensembl chr 6:33,646,075...33,789,532 		JBrowse link
G Becn1 beclin 1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BECN1 protein CTD PMID:23111315 NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002 		JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions ISO
EXP 		[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP protein; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased secretion of BGLAP protein; Ammonium Chloride inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]]; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein; [beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP mRNA; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of BGLAP mRNA; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of BGLAP mRNA]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein]; Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; SMAD4 protein inhibits the reaction [Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP mRNA]]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]] 		CTD PMID:17692823 PMID:23111315 PMID:25932594 PMID:26492236 PMID:27028516 More... NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318 		JBrowse link
G Bmp1 bone morphogenetic protein 1 multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP1 mRNA CTD PMID:15994055 NCBI chr15:51,961,310...52,005,597
Ensembl chr15:51,961,310...52,005,485 		JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions EXP
ISO 		[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein] 		CTD PMID:15994055 PMID:22940495 PMID:23111315 PMID:26492236 PMID:27387537 NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760 		JBrowse link
G Bmp3 bone morphogenetic protein 3 multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP3 mRNA CTD PMID:15994055 NCBI chr14:11,012,564...11,041,282
Ensembl chr14:11,016,620...11,041,282 		JBrowse link
G Bmp7 bone morphogenetic protein 7 multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP7 mRNA CTD PMID:15994055 NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137 		JBrowse link
G Bmpr1a bone morphogenetic protein receptor type 1A multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]] CTD PMID:27387537 NCBI chr16:9,740,751...9,786,861
Ensembl chr16:9,742,875...9,786,861 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of CEBPA protein
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA 		CTD PMID:14505802 PMID:25932594 NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309 		JBrowse link
G Chaf1b chromatin assembly factor 1 subunit B multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of CHAF1B mRNA CTD PMID:26424790 NCBI chr11:46,670,560...46,690,739
Ensembl chr11:46,670,630...46,690,733 		JBrowse link
G Cited1 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA] CTD PMID:28189605 NCBI chr  X:71,390,328...71,395,023
Ensembl chr  X:71,390,331...71,393,649 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA] 		CTD PMID:31935364 PMID:34562440 PMID:34575692 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of CTNNB1 mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of CTNNB1 mRNA]
[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of CTNNB1 mRNA; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of CTNNB1 mRNA]; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]; Lithium Chloride affects the reaction [Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]]; Lithium Chloride affects the reaction [mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of CTNNB1 mRNA]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]; T 0070907 affects the reaction [Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]]; T 0070907 affects the reaction [mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]] 		CTD PMID:28921615 PMID:35738543 NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Dmp1 dentin matrix acidic phosphoprotein 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DMP1 mRNA; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DMP1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA] CTD PMID:25932594 PMID:35738543 NCBI chr14:5,833,111...5,867,154
Ensembl chr14:5,833,111...5,843,993 		JBrowse link
G Dpf1 double PHD fingers 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPF1 mRNA CTD PMID:26424790 NCBI chr 1:93,729,683...93,743,425
Ensembl chr 1:93,726,970...93,743,425 		JBrowse link
G Dppa2 developmental pluripotency-associated 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPPA2 mRNA CTD PMID:28189605 NCBI chr11:66,008,002...66,020,044
Ensembl chr11:66,011,628...66,020,994 		JBrowse link
G Dspp dentin sialophosphoprotein multiple interactions ISO [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DSPP mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DSPP mRNA] CTD PMID:35738543 NCBI chr14:5,870,232...5,876,339
Ensembl chr14:5,870,232...5,876,339 		JBrowse link
G Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 increases expression
multiple interactions
increases activity 		ISO beta-glycerophosphoric acid results in increased expression of ENPP1 mRNA
Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased activity of ENPP1 protein]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of ENPP1 mRNA] 		CTD PMID:18500657 NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ESR1 protein; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ESR1 protein]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ESR1 protein] CTD PMID:28921615 NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354 		JBrowse link
G Ezh1 enhancer of zeste 1 polycomb repressive complex 2 subunit multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of EZH1 mRNA CTD PMID:26424790 NCBI chr10:86,626,307...86,662,257
Ensembl chr10:86,626,308...86,652,620 		JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 protein; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA] CTD PMID:26424790 NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:77,624,223...77,687,183 		JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA] CTD PMID:25062436 PMID:25932594 PMID:32473317 NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972 		JBrowse link
G Fancl FA complementation group L multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of FANCL mRNA CTD PMID:26424790 NCBI chr14:104,449,403...104,515,297
Ensembl chr14:104,394,590...104,515,297 		JBrowse link
G Fgf23 fibroblast growth factor 23 increases expression ISO beta-glycerophosphoric acid results in increased expression of FGF23 mRNA CTD PMID:15542045 NCBI chr 4:161,600,439...161,609,991
Ensembl chr 4:161,600,383...161,609,991 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA]] CTD PMID:27028516 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gdf10 growth differentiation factor 10 multiple interactions EXP [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of GDF10 mRNA CTD PMID:15994055 NCBI chr16:9,243,434...9,256,788
Ensembl chr16:9,243,317...9,256,794 		JBrowse link
G Gpc3 glypican 3 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of GPC3 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of GPC3 mRNA] CTD PMID:28189605 NCBI chr  X:136,789,770...137,157,598
Ensembl chr  X:136,789,770...137,157,639 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of H2AX mRNA CTD PMID:26424790 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hand2 heart and neural crest derivatives expressed 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of HAND2 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of HAND2 mRNA] CTD PMID:28189605 NCBI chr16:37,928,145...37,931,488
Ensembl chr16:37,928,145...37,931,488 		JBrowse link
G Hells helicase, lymphoid specific multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HELLS mRNA CTD PMID:26424790 NCBI chr 1:246,113,580...246,159,230
Ensembl chr 1:246,114,096...246,159,228 		JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HMGB1 mRNA CTD PMID:26424790 NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327 		JBrowse link
G Hmgb2 high mobility group box 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HMGB2 mRNA CTD PMID:26424790 NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]; Hydrogen Peroxide affects the reaction [Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]]; Hydrogen Peroxide affects the reaction [Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]]; Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]; Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]] CTD PMID:27028516 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Ibsp integrin-binding sialoprotein multiple interactions EXP
ISO 		[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA]]
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of IBSP mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of IBSP mRNA] 		CTD PMID:26492236 PMID:27028516 NCBI chr14:5,744,497...5,757,242
Ensembl chr14:5,744,501...5,775,299 		JBrowse link
G Ins1 insulin 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA CTD PMID:25062436 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; tetrabromobisphenol A inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA] 		CTD PMID:25932594 PMID:32473317 NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Msx2 msh homeobox 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of MSX2 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of MSX2 mRNA] CTD PMID:28189605 NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein]; MTOR protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein] CTD PMID:23111315 NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435 		JBrowse link
G Nog noggin multiple interactions EXP NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]] CTD PMID:27387537 NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA] CTD PMID:25932594 NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532 		JBrowse link
G Nsd2 nuclear receptor binding SET domain protein 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of NSD2 mRNA CTD PMID:26424790 NCBI chr14:81,057,727...81,135,866
Ensembl chr14:81,057,727...81,123,027 		JBrowse link
G Parg poly (ADP-ribose) glycohydrolase multiple interactions ISO PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein]; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA] CTD PMID:22940495 NCBI chr16:7,442,696...7,550,585
Ensembl chr16:7,442,726...7,550,584 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of PARP1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of PARP1 mRNA]
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein modified form; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein]; PARP1 mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA] 		CTD PMID:22940495 PMID:26492236 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Phex phosphate regulating endopeptidase X-linked increases expression
multiple interactions 		ISO beta-glycerophosphoric acid results in increased expression of PHEX mRNA
Foscarnet inhibits the reaction [beta-glycerophosphoric acid results in increased expression of PHEX mRNA]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of PHEX mRNA] 		CTD PMID:18500657 NCBI chr  X:41,422,561...41,671,226
Ensembl chr  X:41,426,101...41,671,226 		JBrowse link
G Phf2 PHD finger protein 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PHF2 mRNA CTD PMID:26424790 NCBI chr17:15,989,594...16,057,583
Ensembl chr17:15,981,604...16,057,583 		JBrowse link
G Plin1 perilipin 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA] 		CTD PMID:25932594 PMID:32473317 NCBI chr 1:143,073,612...143,086,199
Ensembl chr 1:143,074,214...143,086,206 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of POU5F1 mRNA CTD PMID:28189605 NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]]; Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA] CTD PMID:14505802 PMID:25932594 PMID:32473317 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Pth1r parathyroid hormone 1 receptor multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PTH1R mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PTH1R mRNA] CTD PMID:28189605 NCBI chr 8:119,572,295...119,597,405
Ensembl chr 8:119,575,868...119,598,108 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; MTOR protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein] CTD PMID:23111315 NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238 		JBrowse link
G Rptor regulatory associated protein of MTOR, complex 1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of RPTOR protein CTD PMID:23111315 NCBI chr10:105,376,943...105,675,416
Ensembl chr10:105,376,943...105,675,413 		JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions
increases expression 		ISO
EXP 		[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA; [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of RUNX2 mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; Ammonium Chloride inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; bisphenol A inhibits the reaction [beta-glycerophosphoric acid results in increased expression of RUNX2 protein]; Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]]; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of RUNX2 mRNA]; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA]; PARP1 mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 protein; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of RUNX2 mRNA; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of RUNX2 protein; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of RUNX2 mRNA]; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of RUNX2 protein]; Lithium Chloride affects the reaction [Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of RUNX2 protein]]; Lithium Chloride affects the reaction [mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of RUNX2 protein]]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of RUNX2 mRNA]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of RUNX2 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA]; Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 protein]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA]; SMAD4 protein inhibits the reaction [Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 protein]]
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]] 		CTD PMID:17692823 PMID:22940495 PMID:23111315 PMID:26424790 PMID:26492236 More... NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027 		JBrowse link
G Satb2 SATB homeobox 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA] CTD PMID:26424790 NCBI chr 9:65,842,351...66,028,569
Ensembl chr 9:65,844,570...66,021,238 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA]]; Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA] CTD PMID:14505802 NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785 		JBrowse link
G Smad1 SMAD family member 1 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD1 mRNA] CTD PMID:26492236 NCBI chr19:45,417,430...45,477,962
Ensembl chr19:45,417,433...45,477,957 		JBrowse link
G Smad2 SMAD family member 2 multiple interactions ISO [beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in decreased phosphorylation of and affects the localization of SMAD2 protein; Particulate Matter promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in decreased phosphorylation of and affects the localization of SMAD2 protein] CTD PMID:38914176 NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388 		JBrowse link
G Smad4 SMAD family member 4 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD4 mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Particulate Matter] results in decreased expression of SMAD4 protein; [beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SMAD4 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD4 mRNA]; Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SMAD4 protein]; SMAD4 protein inhibits the reaction [Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP mRNA]]; SMAD4 protein inhibits the reaction [Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 protein]]; SMAD4 protein promotes the reaction [Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SP7 protein]] CTD PMID:26492236 PMID:38914176 NCBI chr18:69,518,988...69,549,684
Ensembl chr18:69,518,988...69,549,684 		JBrowse link
G Smad5 SMAD family member 5 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD5 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD5 mRNA] CTD PMID:26492236 NCBI chr17:7,867,640...7,896,983
Ensembl chr17:7,871,984...7,890,992 		JBrowse link
G Smad9 SMAD family member 9 multiple interactions ISO [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD9 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD9 mRNA] CTD PMID:26492236 NCBI chr 2:141,106,668...141,156,477
Ensembl chr 2:141,106,668...141,156,477 		JBrowse link
G Smurf1 SMAD specific E3 ubiquitin protein ligase 1 multiple interactions ISO [Particulate Matter co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SMURF1 mRNA CTD PMID:38914176 NCBI chr12:14,748,717...14,840,273
Ensembl chr12:14,749,043...14,840,273 		JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SOX2 mRNA CTD PMID:28189605 NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350 		JBrowse link
G Sox9 SRY-box transcription factor 9 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SOX9 mRNA CTD PMID:26424790 NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250 		JBrowse link
G Sp7 Sp7 transcription factor multiple interactions
increases expression 		ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein; [beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SP7 mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SP7 protein; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein]; Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SP7 mRNA]; Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SP7 protein]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; SMAD4 protein promotes the reaction [Particulate Matter inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SP7 protein]]; tetrabromobisphenol A inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]
beta-glycerophosphoric acid results in increased expression of SP7 protein
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SP7 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; bisphenol A inhibits the reaction [beta-glycerophosphoric acid results in increased expression of SP7 protein]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA] 		CTD PMID:22940495 PMID:25062436 PMID:25932594 PMID:26492236 PMID:32324263 More... NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:135,363,199...135,373,559 		JBrowse link
G Sparc secreted protein acidic and cysteine rich multiple interactions ISO [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein CTD PMID:17692823 NCBI chr10:40,017,065...40,038,816
Ensembl chr10:40,017,075...40,039,268 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPP1 protein; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA]
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SPP1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SPP1 mRNA] 		CTD PMID:17692823 PMID:22940495 PMID:26492236 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the expression of SQSTM1 protein CTD PMID:23111315 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]]; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA]] CTD PMID:14505802 NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA] CTD PMID:25932594 NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164 		JBrowse link
G Stc1 stanniocalcin 1 decreases expression EXP beta-glycerophosphoric acid results in decreased expression of STC1 mRNA CTD PMID:17438129 NCBI chr15:50,709,439...50,720,093
Ensembl chr15:50,709,415...50,720,082 		JBrowse link
G Suv39h1 SUV39H1 histone lysine methyltransferase multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H1 mRNA CTD PMID:26424790 NCBI chr  X:17,093,059...17,105,942
Ensembl chr  X:17,092,986...17,105,942 		JBrowse link
G Suv39h1-ps1 SUV39H1 histone lysine methyltransferase, pseudogene 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H1 mRNA CTD PMID:26424790 NCBI chr  X:146,828,818...146,831,485 JBrowse link
G Suv39h2 SUV39H2 histone lysine methyltransferase multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H2 mRNA CTD PMID:26424790 NCBI chr17:79,665,467...79,684,492
Ensembl chr17:79,665,376...79,684,492 		JBrowse link
G Tafazzin tafazzin, phospholipid-lysophospholipid transacylase multiple interactions ISO [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of TAFAZZIN mRNA CTD PMID:17692823 NCBI chr  X:157,216,826...157,230,524
Ensembl chr  X:157,216,554...157,225,287 		JBrowse link
G Tcf19 transcription factor 19 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of TCF19 mRNA CTD PMID:26424790 NCBI chr20:3,223,464...3,227,569
Ensembl chr20:3,223,324...3,230,060 		JBrowse link
G Tcf20 transcription factor 20 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TCF20 mRNA CTD PMID:26424790 NCBI chr 7:115,833,523...116,009,790
Ensembl chr 7:115,834,416...115,931,915 		JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA] CTD PMID:26424790 NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of and results in increased secretion of TNFSF11 protein CTD PMID:32156525 NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479 		JBrowse link
G Uhrf1 ubiquitin-like with PHD and ring finger domains 1 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of UHRF1 mRNA CTD PMID:26424790 NCBI chr 9:1,220,162...1,241,792
Ensembl chr 9:1,222,063...1,241,792 		JBrowse link
G Uhrf2 ubiquitin like with PHD and ring finger domains 2 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of UHRF2 mRNA CTD PMID:26424790 NCBI chr 1:237,224,050...237,291,406
Ensembl chr 1:237,228,456...237,292,353 		JBrowse link
G Vcl vinculin multiple interactions ISO [Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of VCL protein; Hydroxychloroquine inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of VCL protein] CTD PMID:28975700 NCBI chr15:3,315,069...3,404,891
Ensembl chr15:3,315,069...3,405,163 		JBrowse link
G Wnt1 Wnt family member 1 multiple interactions ISO [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of WNT1 mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of WNT1 mRNA]
[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of WNT1 mRNA; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of WNT1 protein; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of WNT1 mRNA]; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of WNT1 protein]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of WNT1 mRNA]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of WNT1 protein] 		CTD PMID:28921615 PMID:35738543 NCBI chr 7:131,817,558...131,821,605
Ensembl chr 7:131,817,558...131,821,605 		JBrowse link
G Wnt11 Wnt family member 11 multiple interactions ISO [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of WNT11 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of WNT11 mRNA] CTD PMID:28189605 NCBI chr 1:162,545,660...162,565,456
Ensembl chr 1:162,545,680...162,564,660 		JBrowse link
isosorbide dinitrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity ISO Isosorbide Dinitrate results in decreased activity of CYP1A1 protein CTD PMID:33814510 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Edn1 endothelin 1 multiple interactions ISO [Isosorbide Dinitrate co-treated with Plant Preparations] results in decreased expression of EDN1 mRNA CTD PMID:15719745 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases response to substance ISO G6PD protein results in decreased susceptibility to Isosorbide Dinitrate CTD PMID:6401899 NCBI chr  X:157,352,364...157,372,144
Ensembl chr  X:157,352,373...157,372,144 		JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions ISO [Isosorbide Dinitrate co-treated with Ascorbic Acid] affects the expression of NOS3 mRNA; [Isosorbide Dinitrate co-treated with Plant Preparations] results in increased expression of NOS3 mRNA CTD PMID:15719745 NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664 		JBrowse link
isosorbide mononitrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Pafah1b1 platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 multiple interactions EXP isosorbide-5-mononitrate inhibits the reaction [Castor Oil results in increased expression of PAFAH1B1 protein] CTD PMID:8738301 NCBI chr10:60,031,441...60,090,259
Ensembl chr10:60,032,514...60,090,196 		JBrowse link
lysophosphatidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ddr1 discoidin domain receptor tyrosine kinase 1 ISO lysophosphatidic acid increased expression of Ddr1 in 3T3 and GD25 cells RGD PMID:28199848 RGD:151347403 NCBI chr20:3,047,269...3,069,277
Ensembl chr20:3,050,375...3,069,276 		JBrowse link
G Prkd1 protein kinase D1 increases phosphorylation EXP LPA increases phosphorylation of Prkd1 protein in neonatal ventricular myocytes RGD PMID:16648482 RGD:243065275 NCBI chr 6:73,460,640...73,774,433
Ensembl chr 6:73,460,640...73,836,509 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20874
    chemical entity 20872
      atom 20872
        nonmetal atom 20781
          oxygen atom 20437
            oxygen molecular entity 20437
              organooxygen compound 19713
                carbohydrates and carbohydrate derivatives 15263
                  carbohydrate derivative 14522
                    alditol derivative 166
                      alditol phosphate + 161
                      glycosyl alditol derivative + 0
                      heptitol derivative 0
                      hexitol derivative + 5
                      pentitol derivative + 0
                      tetritol derivative + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 20874
    subatomic particle 20883
      composite particle 20883
        hadron 20872
          baryon 20883
            nucleon 20872
              atomic nucleus 20883
                atom 20872
                  main group element atom 20796
                    p-block element atom 20796
                      carbon group element atom 20712
                        carbon atom 20706
                          organic molecular entity 20706
                            heteroorganic entity 20201
                              organochalcogen compound 19822
                                organooxygen compound 19713
                                  carbohydrates and carbohydrate derivatives 15263
                                    carbohydrate derivative 14522
                                      alditol derivative 166
                                        alditol phosphate + 161
                                        glycosyl alditol derivative + 0
                                        heptitol derivative 0
                                        hexitol derivative + 5
                                        pentitol derivative + 0
                                        tetritol derivative + 0
paths to the root